Observational studyThe Journal of dermatology2019
Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: Quality of life and prevalence.
Observational study in The Journal of dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 44 citations in OpenAlex.
- Determinants of Health-Related Quality of Life Among Patients with Psoriasis Vulgaris.Clinical neuropsychiatry · 2026Article
- Association Between Systemic Inflammation, Metabolic Syndrome and Quality of Life in Psoriasis Patients.Life (Basel, Switzerland) · 2025Article
- Gentiopicrin-Loaded Chitosan Nanoparticles as a Topical Agent for the Treatment of Psoriasis.Nanomaterials (Basel, Switzerland) · 2024Article
- Hypertension in connective tissue disease.Journal of human hypertension · 2024Review
- Article
- Association Between Non-HDL to HDL Cholesterol Ratio (NHHR) and Psoriasis in Adults: A Cross-Sectional Study Using 2009-2014 Data.Clinical, cosmetic and investigational dermatology · 2024Article
- Metabolic Syndrome in Psoriasis and Psoriatic Arthritis in a Mixed Race Population: Comparison of Their Prevalences.Psoriasis (Auckland, N.Z.) · 2024Article
- Beliefs about Medicines among a Sample of Iraqi patients with Psoriasis.Innovations in pharmacy · 2021Article
- Interleukin-17A and Keratinocytes in Psoriasis.International journal of molecular sciences · 2020Review
- The place of omega-3 and omega-6 acids in supplementary treatment of inflammatory joint diseases.Reumatologia · 2020Review
- Benefits of Hesperidin for Cutaneous Functions.Evidence-based complementary and alternative medicine : eCAM · 2019Review
- Facing the Unseen - Metabolic Syndrome in Psoriatic Arthritis.Current health sciences journalArticle
- Dietary patterns of patients with psoriasis at a public healthcare institution in Brazil.Anais brasileiros de dermatologiaArticle
- Secukinumab for Psoriasis in Obese Patients: Minireview and Clinical Experience.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 11 institutions in 2 countries.
Funding
Abstract
Interest has increased in comorbidities associated with psoriasis and their effects on health-related quality of life (HRQoL). This study aimed to evaluate the prevalence of metabolic syndrome (MetS) and psoriatic arthritis (PsA) and to investigate HRQoL and the prevalence of hypertension, type 2 diabetes mellitus (T2DM), obesity and dyslipidemia. In a cross-sectional design, patients diagnosed with plaque psoriasis answered an interview and standardized questionnaires (Dermatology Life Quality Index questionnaire [DLQI], 36-Item Short Form Health Survey [SF-36] and EuroQol Five-Dimension Questionnaire Three-Level version [EQ-5D-3L]). Physical examination and several tests to assess desired outcomes were performed by a dermatologist and a rheumatologist during three visits. The prevalence of MetS and PsA was 50.0% and 41.8%, respectively. Dyslipidemia was the most prevalent (74.5%) secondary comorbidity, followed by hypertension (61.8%), obesity (52.5%) and T2DM (30.9%). The mean (standard deviation) DLQI score was 6.5 (6.9), and mean physical and mental SF-36 measures were 45.2 (10.4) and 45.5 (12.3), respectively, and for EQ-5D-3L, mean utility index and EQ-VAS scores were 0.68 (0.27) and 72.7 (19.7), respectively. PsA and MetS are important comorbidities; a reduced HRQoL is noted among plaque psoriasis patients with these comorbidities, emphasizing the relevance of diagnosis and treatment beyond the care of skin lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.